Columns

When I began writing about multiple sclerosis, I never imagined that, one day, I’d be writing a column about guns. But here I am, staring right into that barrel. The other day as I cruised around MS websites, I ran across a post from a woman who was…

In 2004, I was diagnosed with hypothyroidism, a condition in which the thyroid is underactive and doesn’t product enough important hormones. Six years later, I was diagnosed with multiple sclerosis (MS). Naturally, I became curious as to whether a link might exist between between hypothyroidism and MS. I am…

Multiple sclerosis causes debilitating fatigue. The following photographs show, without censorship, what my fatigue leaves undone. The homes of everyone I know have living rooms without sweaters tossed over the back of chairs. Their floors are not an obstacle course. They do not have piles of mail, notes, drills,…

It was three years since I’d seen my best mate Nigel. The last time had been when we said goodbye at London City Airport after our three-day sozzled sojourn (OK, drunken trip) round the Scottish Isle of Islay. To the uninitiated, a pilgrimage for those who worship peat in their…

The American Academy of Neurology‘s (AAN) 2017 annual meeting will bring together physicians who practice in all areas of neurology, including our own multiple sclerosis (MS) specialists. In a recent interview with Anthony Traboulsee, MD, associate professor and research chair of the MS Society of…

(Editor’s note: Tamara Sellman continues her occasional series on the MS alphabet with this third of three parts on terms starting with the letter “C.”) When it comes to multiple sclerosis, mastering an understanding of the disease means you need to mind your Ps and Qs, dot your…

New data on the recently approved multiple sclerosis (MS) drug Ocrevus (ocrelizumab) will be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting 2017, which will take place April 22-28 in Boston. The meeting is the first scientific conference focusing on neurology since the U.S.

This past week has been uplifting. The sun was out and the weather was enjoyable. Spring has officially arrived, and I was able to get out and really appreciate the nice days. I did not do much of anything, however, I was out and about. Easter Sunday was…

I’m an old guy, and it’s been a looonnnggg time since I was diagnosed with multiple sclerosis. This, however, is not the case with BJ Baker. BJ is in his late 20s, and was having a very bad day. He was too tired to do a (seemingly) simple…

It was my 2015 annual check-in, and my neurologist and I were in the exam room. I was sitting on one of those little stools with wheels, he was leaning across the exam table. We had just finished discussing my steadily worsening symptoms and treatment plan, which consisted…

Multiple sclerosis is a very complex disease that attacks the central nervous system. The symptoms MS generates are random, affect everyone differently, and are categorized either as primary MS, or secondary MS, symptoms. Primary MS symptoms are the direct result of the disease itself — byproducts of the damaged…

There are a few moments when life changes. In my day, it was meeting your partner across a crowded room. Now it’s sadly the flick of an app. What hasn’t changed is that only later do you realize this really was a moment. This isn’t a story about romance…

(Editor’s note: Tamara Sellman continues her occasional series on the MS alphabet with this second of three parts on terms starting with the letter “C.”) When it comes to multiple sclerosis, mastering an understanding of the disease means you need to mind your Ps and Qs, dot your Is, cross your Ts,…

A lot has changed in multiple sclerosis research and treatment since I was diagnosed 30 years ago. Here are a few things I was told originally that are no longer true: There’s less than a 1% chance for a child to inherit their mother’s…

T.S. Eliot’s opens his masterwork The Waste Land with four stunning lines of verse: April is the cruellest month, breeding Lilacs out of the dead land, mixing  Memory and desire, stirring  Dull roots with spring rain.  It seems odd to say that April is…

Pamela Arterbridge is one of 70 people at Ohio State University’s Multiple Sclerosis Center taking part in the open-label part of a clinical trial for ocrelizumab, now best known as Ocrevus.  She is a patient of Dr. Michael Racke, who is a pioneer in the field of B-cell treatments for MS,…

You might think that the Fair Housing Act required multifamily buildings to have elevators, but no, it doesn’t. A multifamily dwelling of four units that does not have an elevator is not required to have one. However, the ground floor units must be fully…

The dating process is the prerequisite to most serious relationships. We invest a significant amount of time to assess whether we are compatible with the person of interest. Dating should be fun and we should look forward to future possibilities. For the past few days I’ve been thinking about dating…

With last month’s approval of the multiple sclerosis drug Ocrevus, I’ve again heard the plea “But how can I afford it?” Ocrevus carries a price tag of about $65,000 a year. That’s not high compared to some other MS drugs, but it still can mean a higher…

A popular theory of what contributes to developing multiple sclerosis is a disease called mononucleosis (also known as glandular fever), which can be caused by Epstein-Barr virus (EBV). It is thought that the virus weakens our defenses in the blood-brain barrier, allowing white blood…

Here’s my Pick of the Week’s News, as published by Multiple Sclerosis News Today. Canada, World’s Multiple Sclerosis Capital, Launches 3-Way Collaboration to Research MS Progression Why some people develop primary progressive MS and others have the relapsing type, and why a many relapsing patients develop secondary…

The ABLE Act improvement bills were reintroduced into Congress this week and referred to committee on April 4. The bills died in committee in 2016 before an active campaign could garner enough attention in that election year. I urge all readers in the U.S. to call your representatives and senators to encourage them to…

These might be the days of the gig economy, but I’ve been doing one every Tuesday for 27 years. My particular white van (for US readers the delivery drivers of such are a British stereotype of the new Amazon order — or lack of it) is a comedy vehicle…

There was much fanfare when the multiple sclerosis drug Ocrevus (ocrelizumab) finally was approved by the U.S. Food and Drug Administration last week. Perhaps a little too much fanfare? For example, a story broadcast on the NBC Nightly News focused on a woman, apparently a participant in an…

A prominent neurologist, who was involved in early research into B-cell therapy, tells Multiple Sclerosis News Today about his positive experience of using ocrelizumab, now branded Ocrevus, with patients. Michael Racke, MD, Department of Neurology at The Ohio State University Wexner Medical Center took time to talk with me about…

(Editor’s note: Tamara Sellman continues her occasional series on the MS alphabet with the first in a three-part series of terms starting with the letter “C.”) When it comes to multiple sclerosis, mastering an understanding of the disease means you need to mind your Ps and Qs, dot your…

Ocrevus is a “fabulous” drug that does wonders for those who respond to it. That’s the view of an MS nurse practitioner in Florida, with whom I spoke this week. Tricia Pagnotta works at the Multiple Sclerosis…

I was a teenager during the 1980s and cannot say the word “holiday” without Madonna’s song playing briefly in my head. For most holidays the perky music seems okay, but for discussion of a “drug holiday” it feels a bit off. Sort of like, “Yay! You have a chronic…

“Is the MS drug news good for u?” my friend’s text asked. It was Wednesday morning, March 29. Genentech had just announced  that Ocrevus, the “First and only approved disease-modifying therapy for primary progressive form of multiple sclerosis (PPMS) – one of the most disabling forms of…

The past few days have been remarkable in the multiple sclerosis (MS) community, with the U.S. Food and Drug Administration (FDA) approving Ocrevus to treat relapsing MS (RRMS) and primary progressive MS (PPMS) in the United States. Ocrevus — adminstered intravenously every six months — is the first drug…